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Objective. The purpose of this study was to evaluate acute
angiographic success, in-hospital complications and long-term
outcome after intracoronary stenting in patients with cardiac
allograft vasculopathy.
Background. The application of conventional interventional
modalities to treat discrete lesions in patients with cardiac
allograft vasculopathy is associated with higher procedural mor-
bidity, mortality and higher restenosis compared to atheroscle-
rotic coronary artery disease. Elective coronary stenting has been
shown to lower restenosis rates and improve long-term outcome in
selected patients with native coronary artery disease; however, its
safety and efficacy in reducing restenosis in patients with cardiac
allograft vasculopathy is unknown.
Methods. Ten patients with 19 discrete lesions in a major coronary
artery without diffuse distal disease underwent intracoronary stent-
ing using Palmaz–Schatz stents. The average stent size was 3.4 mm,
and the stent/artery ratio was 0.99 6 0.07. Eight of ten (80%) patients
received antiplatelet therapy (aspirin plus ticlopidine) only.
Results. Procedural success was 100% with no in-hospital stent
thrombosis, Q-wave myocardial infarction or death. Minimal
luminal diameter increased from 0.83 6 0.38 mm to 3.23 6
0.49 mm after stenting. Diameter stenosis decreased from 74.91 6
11.52% to 5.90 6 4.09% after stenting. Follow-up angiography was
performed in 8 of 10 (80%) patients and 16 of 19 (84%) lesions.
Target lesion revascularization was required in 2 of 10 (20%)
patients and 3 of 16 (19%) lesions. Allograft survival was 7 of 10
(70%) at the end of 22 6 11 months follow-up.
Conclusions. Intracoronary stenting can be performed safely
with excellent angiographic success in selected patients with
cardiac allograft vasculopathy. The restenosis rate appears to
be low despite the aggressive nature of the disease. A multi-
center study with a larger number of patients is required to
assess its efficacy in reducing restenosis and improving allo-
graft survival.
(J Am Coll Cardiol 1998;32:1636–40)
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Cardiac allograft vasculopathy (CAV) represents an acceler-
ated form of obstructive coronary artery disease and remains
an obstacle to the long-term survival of cardiac transplant
recipients (1–5). Unlike atherosclerotic coronary artery dis-
ease, treatment options are limited due to the progressive and
diffuse nature of CAV. Retransplantation was initially used in
patients with severe CAV; however, with a 55% survival at 1
year and a 46% incidence of recurrent CAV in those who
survived, it is no longer recommended in many centers (6).
Pharmacologic interventions to prevent CAV progression have
been unsuccessful, with the exception of diltiazem, a calcium
channel blocker (7). Recently, two studies have shown that
3-hydroxy-3-methylglutaryl-coenzymeA (HMG-Co-A) reduc-
tase inhibitors (pravastatin and simvastatin) can reduce the
incidence of CAV and graft rejection and can increase long-
term survival in cardiac transplant recipients (8,9). Balloon
angioplasty, directional atherectomy and coronary bypass
grafting have been used as palliative measures to reduce
CAV-related morbidity and mortality (10–12). However, all
these techniques have higher procedural morbidity and mor-
tality and higher restenosis compared to atherosclerotic coro-
nary artery disease.
Elective coronary stenting has been shown to achieve
excellent angiographic success, to lower the restenosis rate and
to improve long-term outcome compared to balloon dilatation
alone in selected patients with native coronary artery disease
(13,14); however, its safety and efficacy in reducing cardiac
morbidity and mortality in patients with CAV is unknown. The
purpose of this study was to evaluate acute angiographic
success, in-hospital complications and long-term efficacy of
intracoronary stenting in patients with CAV.
Methods
Patient population. The study group consisted of 10 pa-
tients who underwent intracoronary stenting for CAV between
March 1994 and April 1997. These patients were selected from
34 of 120 (28.3%) cardiac transplant recipients who were
found to have lesions suitable for percutaneous revasculariza-
tion. Patients with discrete lesions (.50% diameter stenosis,
lesion length ,12 mm, a vessel diameter $3.0 mm) in the
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proximal or midvessel without diffuse distal disease were
selected for intracoronary stenting. Clinical and demographic
characteristics of the patients are shown in Table 1. All
patients received immunosuppression with cyclosporine, aza-
thioprine and prednisone. Eight of the 10 patients were also
receiving HMG-CoA reductase inhibitor. Indications for cor-
onary angioplasty were angiographic stenosis (n 5 3) with
provocable ischemia in the vascular territory of the stenotic
artery, angina pectoris (n 5 5) and following myocardial
infarction in two patients with severe residual stenosis.
Procedural details. All patients underwent balloon angio-
plasty and stent implantation according to the standard clinical
practice by the femoral approach. A bolus of 10,000 units of
intravenous heparin was given at the beginning of the proce-
dure and further supplemented to maintain an activated
clotting time of 250 to 300 s. Selection of the balloon catheter
was at the discretion of the operator. Stent size was selected
based on the diameter of the proximal reference vessel.
Primary stenting was performed in seven patients, and three
patients had stenting for the suboptimal results following
directional atherectomy (n 5 2) and balloon angioplasty (n 5
1). A total of 19 lesions were treated. Lesion locations are
shown in Figure 1. Poststent balloon dilatation was performed
at a mean of 14 6 4 atm (range 8 to 20 atm). Poststent
antithrombotic regimens at discharge included a combination
of aspirin (325 mg/day), dipyridamole (75 mg three times/day)
and coumadin for 2 months and then aspirin alone indefinitely
in two patients. The remaining eight patients received a
combination of aspirin (325 mg/day) and ticlopidine
(500 mg/day) for 1 month, and then aspirin indefinitely. None
of the patients received abciximab during the procedure.
Twelve-lead electrocardiograms were recorded before, imme-
diately after and 24 h after the procedure. Serum creatinine
kinase (CK) and myocardial band isoenzyme levels were
measured before the procedure and repeated at 8-h intervals
for 24 h.
Definitions. A significant lesion was defined as .50%
diameter stenosis in either the left anterior descending artery,
left circumflex, right coronary artery or a major branch. Distal
vessel disease was defined as the presence of diffuse concentric
narrowing or diffusely diseased irregular and nontapered le-
sion of a tertiary vessel as defined by Gao et al. (15).
Procedural success was defined as #20% residual diameter
stenosis without in-hospital stent thrombosis, Q-wave myocar-
dial infarction, emergency bypass surgery or death. Q-wave
myocardial infarction was diagnosed by appearance of new
pathologic Q waves in two contiguous electrocardiographic
leads and a CK level greater than twice the upper limit of
normal. Non–Q-wave myocardial infarction was defined as
greater than or equal to a twofold increase in total CK level
without pathologic Q waves. Vascular complications were
defined as a hematoma requiring blood transfusion or pseu-
doaneurysm diagnosed clinically and/or by color Doppler
ultrasound.
Angiographic analysis. An automated edge detection tech-
nique was used for quantitative angiographic analysis from a
diastolic cine frame which included measurements of reference
vessel diameter, minimal luminal diameter (MLD), lesion
length and percent diameter stenosis. The acute gain was
defined as the difference between the MLD after stenting and
the MLD at baseline. The late loss was defined as the
difference between the poststent MLD and the MLD at the
follow-up angiography.
Follow-up. All patients were followed in the outpatient
clinic. Follow-up angiography was performed at 6 to 12 months
or earlier when indicated. The primary end point was angio-
graphic evidence of restenosis ($50% diameter stenosis)
within the stent. Allograft survival was defined as the absence
of retransplantation or death.
Statistical analysis. Continuous variables were expressed
as mean 6 SD. Discrete variables were expressed as percent-
ages. The cumulative frequency curve for MLD was processed
using JMP software version 3.2.2 (SAS Institute, Inc., Cary,
North Carolina).
Results
Procedural success and complications. Twenty-one 15 mm
Palmaz–Schatz (Johnson and Johnson Interventional Systems,
Warren, New Jersey) stents were placed in 19 lesions. The
average stent size was 3.4 mm, and the stent/artery ratio was
0.99 6 0.07. Procedural success was achieved in all (100%)
lesions (Fig. 2). One patient developed a non–Q-wave myocar-
dial infarction following occlusion of a small side branch at the
stent site. None of the patients had a Q-wave myocardial
infarction, in-hospital stent thrombosis, emergency bypass
surgery or a vascular complication.
Quantitative angiography. The reference vessel diameter
was 3.41 6 0.48 mm and mean lesion length was 6.94 6
1.88 mm. Baseline MLD was 0.83 6 0.38 mm, which increased
Table 1. Demographic and Clinical Characteristics
Age* 57 6 6 years
Time since transplantation* 5 6 2 years
Male 8 (80%)
Female 2 (20%)
Diabetes 2 (20%)
Hypertension 8 (80%)
Hypercholesterolemia (.200 mg/dl) 8 (80%)
Current smoker 1 (10%)
LVEF (%)* 49 6 11
*Mean 6 SD. LVEF 5 left ventricular ejection fraction.
Abbreviations and Acronyms
CAV 5 cardiac allograft vasculopathy
CK 5 creatinine kinase
HMG Co-A 5 hydroxymethylglutaryl coenzyme A
MLD 5 minimal luminal diameter
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to 3.23 6 0.49 mm after stenting, thus giving rise to an acute
gain of 2.39 6 0.69 mm. Similarly, percent diameter stenosis
was reduced from 74.91 6 11.52% to 5.90 6 4.09% after
stenting.
Angiographic follow-up. Follow-up angiography was per-
formed in 8 (80%) patients (symptomatic 5 2, asymptomatic 5
6) and in 16 of 19 lesions at 8.5 6 3.7 months. The mean late
loss (the decrease in absolute diameter from immediate post-
stenting to follow-up angiography) was 1.06 6 0.8 mm, result-
ing in an average late luminal diameter of 2.21 6 0.67 mm. The
corresponding mean diameter stenosis was 28.81 6 19.28%.
The cumulative frequency distribution curve of the MLD
measured before and after stenting and at follow-up is shown
in Figure 3. In-stent restenosis was noted in 2 of 10 (20%)
patients and in 3 of 16 (19%) lesions. All three restenotic
lesions were successfully dilated using balloon angioplasty.
Long-term follow-up. Clinical follow-up was available in 10
of 10 (100%) patients. Seven (70%) of the 10 patients were
alive without bypass surgery/retransplantation at a mean dura-
tion of 22 6 11 months (range 9 to 45) after stenting. One
patient died at 9 months from intractable congestive heart
failure and follow-up angiography was not available. Two
patients underwent bypass surgery in combination with
transmyocardial laser revascularization and retransplantation
for progession of CAV 16 and 17 months after stenting,
respectively. The stent site was patent in both of these patients.
Discussion
Cardiac allograft vasculopathy morphology and limitations
of conventional angioplasty modalities. Cardiac allograft vas-
culopathy is a heterogeneous disease with varied morphologic
expression ranging from concentric, diffusely obliterative le-
sions of distal vessels and branches to focal stenoses involving
proximal vessels (16). Histopathologic studies have demon-
strated that discrete stenoses are more likely to consist of
lipid-rich atheromatous plaques, whereas diffuse disease typi-
cally is characterized by severe fibrous intimal thickening (17).
The morphologic features of these lesions as assessed by
coronary angioscopy and intravascular ultrasound also differ
Figure 1. Lesion location of the stented arteries.
LM 5 left main coronary artery (n 5 1); LAD 5 left
anterior descending artery (n 5 8); diagonal artery
(n 5 3); LCx 5 left circumflex artery (n 5 2); RCA 5
right coronary artery (n 5 5).
Figure 2. Upper panel demonstrates
stenting of a mid left anterior descend-
ing artery (LAD) lesion in a patient
who is 4 years posttransplant; (A)
Baseline angiogram showing a severe
stenosis (arrow) in the midLAD re-
gion; (B) Poststent angiographic frame
showing no residual stenosis (arrow);
(C) Angiographic follow-up (F/U) at 6
months shows a patent lumen (arrow)
without any restenosis. Lower panel
demonstrates stenting of a left main
coronary lesion in a patient who pre-
sented with unstable angina 6 years
after cardiac transplant; (A) Baseline
angiogram showing a severe stenosis in
the body of the left main coronary
artery; (B) After placement of a 4-mm
stent; (C and D) Follow-up angiogra-
phy at 6 months and 2 years, respec-
tively, showing minimal luminal nar-
rowing within the stent.
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significantly (18). The presence of isolated discrete stenoses
(.50%) in the proximal or midvessel have been shown to
adversely affect long-term survival (4). Therefore, traditional
interventional modalities, such as balloon angioplasty and
directional atherectomy, have been used in cardiac transplant
patients with discrete lesions (10–12). In contrast to native
coronary arteries, procedural morbidity, mortality and resten-
osis rates are significantly higher in patients with CAV, thereby
limiting the long-term benefits in terms of repeat revascular-
ization and graft survival (10–12).
Rationale for stenting: a comparison with previous studies.
Data regarding the role of intracoronary stenting in CAV is
limited to a single case report and, therefore, has not been
systematically explored (19). This study is the first series to
demonstrate that intracoronary stenting is a safe and feasible
alternative to balloon angioplasty and directional atherectomy
in selected patients with CAV. Procedural success was 100%
with no periprocedural death, stent thrombosis, Q-wave myo-
cardial infarction or emergency bypass surgery. The residual
diameter stenosis was 6 6 4%, and only 19% of the lesions
developed restenosis. In contrast, procedural success with
balloon angioplasty has varied from 85% to 94%, with a 3%
incidence of periprocedural death due to myocardial infarction
(10–12). The average residual diameter stenosis following
balloon angioplasty is 30% (range 8% to 46%) (10–12). In the
multicenter study report by Halle et al. (12), 55% of the lesions
(65% angiographic follow-up) developed restenosis. Intracoro-
nary stenting of discrete lesions in CAV appears to be associ-
ated with excellent procedural success without any major
complications, a larger acute gain in luminal diameter and a
lower restenosis rate than balloon angioplasty. By providing a
metallic “scaffold” to the coronary lumen, intracoronary stent-
ing minimizes plaque disruption which can lead to abrupt
closure, myocardial infarction and death, as noted in CAV
patients undergoing balloon angioplasty and directional
atherectomy (10–12). The acute gain (2.39 6 0.69 mm), late
loss (1.06 6 0.8 mm) and restenosis (20%) following stenting
in our series are comparable to those reported for native
coronary artery stenting (13–14). Thus, it appears that the
reduction in restenosis in our group of patients was due to a
larger acute gain following stenting. During the clinical follow-
up, 70% of the patients were free from retransplantation or
death at a mean duration of 22 months following stent
implantation, a promising result when compared to those
reported in prior studies of balloon angioplasty (10–12). By
preserving luminal patency and reducing the rate of repeat
revascularization, stenting may improve allograft survival in
patients with discrete lesions.
Influence of HMG-CoA reductase inhibitors. In the
present study, 8 of 10 patients were on HMG-CoA reductase
inhibitors, which may have contributed to the overall improved
long-term outcome. Two prospective, randomized studies have
shown that HMG-CoA reductase inhibitors can reduce the
incidence of CAV and prolong graft survival in cardiac trans-
plant recipients independent of plasma cholesterol levels (8,9).
Both studies demonstrated a significant reduction in intimal
proliferation by intravascular ultrasound studies in patients
receiving HMG-CoA reductase inhibitors. The various mech-
anisms by which HMG-CoA reductase inhibitors prevent CAV
progression and prolong graft survival include a decrease in
natural-killer-cell cytotoxicity (8,20) and inhibition of farnesy-
lation of ras-proteins which are essential for the induction of
cell growth by fibroblasts and smooth muscle cells in the
allograft arteries (21,22). It is likely that these mechanisms may
have retarded intimal proliferation within the stented sites and
may be partly responsible for the lower late loss observed in
the present series despite the aggressive nature of CAV.
Figure 3. Cumulative frequency of
minimal luminal diameter at base-
line, immediately after stent im-
plantation and at follow-up.
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Study limitations. The present study has several limita-
tions. First, it is a single center, nonrandomized, uncontrolled
observational study. Second, the number of patients is small;
however, the population of cardiac transplant recipients with
discrete lesions without distal disease is also limited. Third,
angiographic follow-up was available in only 84% of the
lesions. Lastly, the average vessel size was .3.0 mm, which may
have contributed to the reduced restenosis rate and therefore
these results may not be applicable to patients with smaller
vessel size. Despite these limitations, this is the first study to
show that intracoronary stenting can be used safely and
effectively in treating discrete stenoses in CAV.
Conclusions. This preliminary study shows that intracoro-
nary stenting in selected patients with cardiac allograft vascu-
lopathy is safe, technically feasible and provides excellent
immediate angiographic results. The acute gain and late loss
are similar to those reported for native coronary artery stent-
ing. The restenosis rate appears to be low despite the aggres-
sive nature of the disease. Concomitant treatment with HMG-
CoA reductase inhibitors may be beneficial in terms of
reducing in-stent intimal proliferation and may act synergisti-
cally in prolonging graft survival. A multicenter study with a
larger number of patients is needed to validate the long-term
efficacy of intracoronary stenting in reducing restenosis and in
improving graft survival.
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